CSL324
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03972280)
Timeline
Indications
Mechanism of action
Granulocyte colony stimulating factor receptor antagonist
CSF3R inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650461 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07224360 | Phase 2 | Nov 15, 2025 | CSL Behring |
| NCT05653713 | Phase 1 | Dec 31, 2022 | CSL Behring |
| NCT04570267 | Phase 1 | Oct 8, 2020 | CSL Behring |
| NCT04519424 | Phase 2 | Sep 30, 2020 | CSL Behring |
| NCT03972280 | Phase 1 | Jun 30, 2019 | CSL Behring |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CSL Behring | For profit | 5 | 5 | 2 | 2019 |
1 organizations
Page 1 / 1